The role of vascular endothelial growth factor (VEGF) in AIDS-related Kaposi's sarcoma

Oncologist

Volumn 5, Issue SUPPL. 1, 2000, Pages 28-31

  Arastéh, Keikawus ^a   Hannah, Alison ^b  

^a Vivantes Auguste Viktoria Klinikum   (Germany)

^b SUGEN INC   (United States)

Author keywords

AIDS related Kaposi's sarcoma; Angiogenesis; Angiogenesis inhibitor; Phase I clinical studies; VEGF; VEGF Flk 1 KDR receptor

Indexed keywords

3 [(4,5 DIMETHYL 1H PYRROL 2 YL)METHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; KAPOSI SARCOMA; MALE; PATHOGENESIS; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 0034003716     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-suppl_1-28     Document Type: Conference Paper

References (33)

1. Masood R, Cai J, Zheng T et al. Vascular endothelial growth factor/vascular permeability factor is an autocrine growth factor for AIDS-Kaposi sarcoma. Proc Natl Acad Sci USA 1997;94:979-984.
2. McGarvey ME, Tulpule A, Cai J et al. Emerging treatments for epidemic (AIDS-related) Kaposi's sarcoma. Curr Opin Oncol 1998;10:413-421.
3. Bower M, Fox P, Fife K et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999;13:2105-2111.
4. Kaplan LD, Hopewell PC, Jaffe H et al. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J Acquir Immune Defic Syndr 1988;1:23-30.
5. Gill PS, Akil B, Collelti P et al. Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. Am J Med 1989;87:57-61.
6. Ensoli B, Sirianni MC. Kaposi's sarcoma pathogenesis: a link between immunology and tumor biology. Crit Rev Oncog 1998;9:107-124.
7. Boshoff C. Kaposi's sarcoma. Coupling herpesvirus to angiogenesis [news; comment]. Nature 1998;391:24-25.
8. Gallo RC. The enigmas of Kaposi's sarcoma. Science 1998;282:1837-1839.
9. Samaniego F, Markham PD, Gendelman R et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998;152:1433-1443.
10. Ambs S, Bennett WP, Merriam WG et al. Vascular endothelial growth factor and nitric oxide synthase expression in human lung cancer and the relation to p53. Br J Cancer 1998;78:233-239.
11. Fujimoto J, Sakaguchi H, Hirose R et al. Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer 1999;80:827-833.
12. Petruzzelli GJ, Benefield J, Taitz AD et al. Heparin-binding growth factor(s) derived from head and neck squamous cell carcinomas induce endothelial cell proliferations. Head Neck 1997;19:576-582.
13. Kranz A, Mattfeldt T, Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999;84:293-298.
14. Valtola R, Salven P, Heikkila P et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999;154:1381-1390.
15. Wong MP, Cheung N, Yuen ST et al. Vascular endothelial growth factor is upregulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999;81:845-850.
16. Fox SH, Whalen GF, Sanders MM et al. Angiogenesis in normal tissue adjacent to colon cancer. J Surg Oncol 1998;69:230-234.
17. Borgstrom P, Bourdon MA, Hillan KJ et al. Neutralizing antivascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate 1998;35:1-10.
18. Tomisawa M, Tokunaga T, Oshika Y et al. Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma. Eur J Cancer 1999;35:133-137.
19. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 1991;138:213-221.
20. Stacker SA, Vitali A, Caesar C et al. A mutant form of vascular endothelial growth factor (VEGF) that lacks VEGF receptor-2 activation retains the ability to induce vascular permeability. J Biol Chem 1999;274:34884-34892.
21. Albini A, Soldi R. Giunciuglio D et al. The angiogenesis induced by HIV-1 Tat protein is mediated by the Flk-1/KDR receptor on vascular endothelial cells. Nat Med 1996;2:1371-1375.
22. Brown LF, Tognazzi K, Dvorak HF et al. Strong expression of kinase insert domain-containing receptor, a vascular permeability factor/vascular endothelial growth factor receptor in AIDS-associated Kaposi's sarcoma and cutaneous angiosarcoma. Am J Pathol 1996;148:1065-1074.
23. Flore O, Rafii S, Ely S et al. Transformation of primary human endothelial cells by Kaposi's sarcoma-associated herpesvirus [letter]. Nature 1998;394:588-592.
24. Marchio S, Primo L, Pagano M et al. Vascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi's sarcoma cells. J Biol Chem 1999;274:27617-27622.
25. Sakurada S, Kato T, Mashiba K et al. Involvement of vascular endothelial growth factor in Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Jpn J Cancer Res 1996;87:1143-1152.
26. Arora N, Masood R, Zheng T et al. Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells. Cancer Res 1999;59:183-188.
27. Ganju RK, Munshi N, Nair BC et al. Human immunodeficiency virus tat modulates the Flk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells. J Virol 1998;72:6131-6137.
28. Barillari G, Sgadari C, Palladino C et al. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin. J Immunol 1999;163:1929-1935.
29. Fife K, Howard MR, Gracie F et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre. Int J STD AIDS 1998;9:751-755.
30. Dezube BJ, Von Roenn JH, Holden-Wiltse J et al. Fumagillin analog in the treatment of Kaposi's sarcoma: a phase I AIDS Clinical Trial Group study. J Clin Oncol 1998;16:1444-1449.
31. Fong TAT, Shawver LK, Sun L et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999;59:99-106.
32. Rosen L, Mulay M, Mayers A et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies. J Clin Oncol 1999;18:161a.
33. Gill P, Arastéh K, Jacobs M et al. A multicenter, dose-escalating study in patients with AIDS-related Kaposi's sarcoma. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy 1999;490a.